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Abstract
Treg cells CD4+CD25+FOXP3+ have a specific function in the tolerance of autoantigens 
and regulation of the immune response. Modulation of differentiation pathways and 
the use of Treg cells in cell therapy have been reported in autoimmune diseases, sys-
temic lupus erythromatosis, autoimmune hepatitis, type 1 diabetes mellitus, multiple 
sclerosis, rheumatoid arthritis, graft-versus-host disease, bone marrow transplantation 
and solid organs. The expansion of Treg cells in vivo occurs through low-dose IL-2 treat-
ment. However, because of the heterogeneity and variability of Treg cells, the isolation of 
peripheral blood cells, through the technique of leucopheresis by GMP (good manuring 
practice), for in vitro expansion is difficult, necessitating a large combination of specific 
and reliable cellular markers. Currently, two specific markers, Helios and neuropilin-1, 
are being studied to facilitate the differentiation of thymus Treg cells and peripheral Treg 
cells. However, Treg cells induced in vitro are unstable. Modulation of the FOXP3 gene 
in the CNS1 and CNS2 region is an alternative to maintaining the stability of expanded 
Treg cells in vitro.
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1. Introduction
Regular T lymphocytes (Treg) were first described in the year 1970 in murine models [1]. They 
are subpopulations of T lymphocytes defined by the expression of CD4+ and CD25+ molecules, 
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as well as by the transcription factor FOXP3 (forkhead box P3). Treg cells maintain self-toler-
ance and immune homeostasis through immune responses against self and non-self antigens 
and in fetal-maternal self-tolerance. Regulation of the immune response occurs through sup-
pression of effector T cells, minimizing the production of cells of adaptive immunity and 
innate immunity [2, 3]. The suppressor function of Treg cells is directed by the transcription 
factor FOXP3, occurring in a non-random manner. However, a deregulation in the Treg cells 
can make them autoreactive with the recognition of autoantigens, developing autoimmune 
diseases [4]. The organism acts naturally against self-reactive T cells through the process of 
negative selection by inactivation or clonal deletion in the thymic tissue, and genetic muta-
tions contribute to self-tolerance in the thymus [5].
FOXP3 expression is initiated through a combination of antigen recognition, microenviron-
mental influences, and epigenetic factors. FOXP3 is present in about 10–20% of the T cells. 
Peripheral induction of FOXP3 expression may occur in the colon and placenta [6, 7]. Treg 
cells exhibit high expression of the IL-2α receptor (CD25) and low expression of CD127 [8]. 
Changes or loss of FOXP3 is associated with the development of collagenases and vasculitis, 
rheumatoid arthritis, mixed connective tissue disease, Kawasaki disease, Wegener's granulo-
matosis, systemic lupus erythematosus and Sjögren's syndrome, enteropathies, type 1 diabe-
tes, thyroiditis and eczema [9]. The various clinical alterations of which Treg cells are present, 
the use of Treg as cell therapy with in vitro and ex vivo expansion has been a research alterna-
tive for certain treatments with the development of tolerance and autoimmunity [10].
2. Treg cell heterogeneity
Treg cells account for 5–10% of peripheral CD4+ T cells in humans and rats. Treg cells that 
grow in the thymus are called natural (nTreg) or thymic (tTreg) Tregs, and Treg cells that 
develop at the periphery by specific stimuli of conventional CD4+ T cells are termed pTreg 
cells. When Treg cells are induced in vitro are called iTreg [11]. Treg cell generation in the thy-
mus and peripheral tissues occurs in response to T cell receptor (TCR) and cytokine receptor 
signaling. Natural Treg cells are generated during the period of positive selection of CD4+ T 
cells by expression of the transcription factor of the FOXP3 gene in the thymus. FOXP3 expres-
sion is controlled by conserved noncoding sequences (CNS) in the promoter region of the 
gene and by intronic regulatory sequences [12]. TGF-β, IL-2, and TCR are required for FOXP3 
gene expression during cell differentiation [13]. The promoter region of the FOXP3 gene is 
activated by the NF-kB pathway, NFAT (nuclear factor of activated T), the transcription fac-
tor SMAD-3, the retinoic acid produced by dendritic cells and epithelial cells, rapamycin and 
NR4As proteins [14–16].
However, there is a small portion of Treg that does not express FOXP3 is known as regu-
latory T type 1 (Tr1) with phenotype CD41+CD49b1+LAG-31+CD2261+FOXP3−. These cells 
are induced by the chronic activation of CD4+ by antigens in the presence of IL-10 and are 
responsible for peripheral immunotolerance. It is possible to distinguish the Tr1 from other 
CD4+ populations from the expression of the cytokines: IL-10++TGF-b+IFN-γ+IL-5+IL-4 
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IL-2−low/neg [10]. T cells expressing FOXP3 circulate through the secondary lymphoid tis-
sues as "central" Tregs. Activation signals involving T cell receptors (TCR), co-stimulation of 
CD28 and/or interleukin-2 (IL-2) induce positive regulation of interferon regulating factor 4 
(IRF4) expression, promoting the differentiation of Treg cells "central" in "effector" Treg cells. 
Unknown stimuli induce the polarization of Treg cells by upregulation of transcription fac-
tors that may act in conjunction with FOXP3 to induce the expression of chemokine receptors 
that mediate recruitment to tissues or sites of inflammation [17, 18]. During activation of TCR 
in a cytokine medium, T CD4+ cells can differentiate into various T cell lines, T helper (Th), 
including Th1, Th2, Th17, Th17, and iTreg, as defined by their production standard and function 
of cytokines [19].
Thymic Treg cells are generated in the medulla and/or the medullo-cortex junctions in the 
thymus and arise from a thimocyte CD4+CD8−. TCR plays an essential role in the differentia-
tion of Treg cells, but it does not act alone. TCR signaling along with co-stimulation of nuclear 
factor activated T-cell (NF-AT), an activator of protein-1 (AP-1) and CARMA1/Bcl10/Malt1 
NF-kB, acts on the FOXP3 gene to induce its expression. In addition, signaling via tumor 
growth factor β (TGF-β), interleukin-2 (IL-2) and transcription activator-5 (STAT5) induce 
signs of stimuli for expression of the Foxp3 gene, so that differentiation of naive T occurs 
Treg. Through stimuli by TGF-β tTreg can differentiate into pTreg [20–22]. The deficiency 
of TCR signaling mediators such as TAK1, Bcl10, CARMA1, PKCh, and IKKb reduces the 
number of Treg cells generated in the thymus without affecting the generation of conven-
tional T cells. This decrease in Treg compromises immunotolerance and equilibration of the 
immune  system [23].
2.1. Treg cell subtypes
Treg naive cells are recognized by the phenotype FOXP3loCD45RA+CD45RO−, and Treg 
cells are FOXP3hiCD45RA−CD45RO+ and express both the Fas receptor (CD95) and cyto-
toxic T-lymphocyte antigen (CTLA-4). A small part of Treg has a phenotype ICOS+IL-10+. 
Treg cells expressing FOXP3 exhibit their immunoregulatory activity by a variety of effector 
mechanisms such as CTLA-4 uptake, IL-2 uptake, IL-10, TGF-β, IL-35 and galactin-1 pro-
duction. The environment in which Treg cells are found alters the mechanisms by which 
they exert suppressive activity. Identification of CD45RA or CD45RO molecules, when 
combined with CD25 and/or FOXP3, is useful for identifying naive reg T cells. Human 
CD45RO+CD25hiCD4+Treg cells are similar to rat Treg cells in CD25 expression. The Treg 
CD45RA+FOXP3+ and CD45RO+FOXP3+ cells are functionally different but are related to the 
development of immunosuppression. Expression of the transcription factor of the B lympho-
cyte-induced maturation protein (Blimp-1) is common to all Treg cells [15, 24–26].
Differentiation of naive Treg gives rise to subtypes of Treg CD4+CD25FOXP3+: tTreg, pTreg, 
and iTreg. With the use of Treg cells in the therapy of human diseases, it is important to 
distinguish between cell subtypes. Expression in the Helios molecule can be effective in dif-
ferentiating between the subtypes of tTreg and iTreg/pTreg [21]. Helios is expressed in the 
thymus, so it may be a marker to identify tTreg from the other populations of Treg, and it 
acts as upregulation in FOXP3 protein [27–29]. However, the Helios molecule can be found 
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in iTregs and pTregs depending on the type of antigen presenting cells and signals found. 
Cells that super-expression Helios have a superior effect of peripheral immunosuppression. 
This feature can be used in treatments for autoimmune diseases such as systemic lupus ery-
thematosus (SLE) and rheumatoid arthritis (RA) [30]. Through in vitro induction of Helios in 
Treg cells, it was found that CD103 and GITR are expressed at high levels in a subset of cells 
Treg Helios+. These markers together can be used to differentiate Treg subtypes from each 
other [21, 31]. Another alternative, the Nrp1 protein (neuropilin-1) is expressed in tTreg cells 
as opposed to iTreg and pTreg cells [31].
The pTreg cells are present in the intestine and mucosa. Dendritic cells present in the mucosa, 
especially CD103+ induce FOXP3+ Tregs through the production of TGF-β and retinoic acid 
[32]. Retinoic acid binds to its receptor, RAR, generating induction signals in the CNS1 region 
of the FOXP3 gene. This signal induction leads to increased histone acetylation in the region 
of the CNS1, the SMAD3 binding sites, and increased phosphorylated SMAD3 binding, 
inducing expression of FOXP3, and originating pTreg cells in the gut. The microbiota also 
promotes cell differentiation of TCD4+ in Treg CD4+FOXP3+. Most of the Tregs in the intes-
tine coexpress FOXP3 and RORgt, a Th17 regulator, as well as T-bet, GATA3 or IRF4, proteins 
that present suppression role in the Th1/Th2 response, maintaining the immunological toler-
ance and acting in the resistance to pathological infections originated microorganisms present 
in the mucosae [33].
2.2. FOXP3 and autoimmunity
FOXP3 is the main labeled Treg cell. The key role of FOXP3 in the immune response of Treg 
has been described in patients with immune dysregulation, polyendocrinopathy, enteropa-
thy, X-linked (IPEX) and in rats scurfy [34, 35]. Patients and scurfy mice present monogenic 
mutations in the FOXP3 gene, which confers a phenotype with dysregulation of the immune 
system with the development of autoimmunity due to lack of Treg cells [36, 37]. Patients with 
IPEX present mutations in a Phe367 residue of the F367V protein, F367L, and F367C, which 
make up the FOXP3 protein [38]. Polymorphic changes in the promoter region of the FOXP3 
gene contribute to loss of function and dysregulation of FOXP3, as well as the development 
of polygenic autoimmune diseases [39]. However, there is no dominant mechanism for the 
development of autoimmunity. Factors affecting FOXP3 function, effects of genetic altera-
tions, altered signaling, and expression of FOXP3 messenger RNA (mRNA) or mature protein 
are related to the development of autoimmunity with an imbalance between conventional 
Treg cells and pathogenic Tregs [40].
IPEX is a rare genetic disease resulting from the lack of functional Treg cells due to the loss 
of functional mutations in FOXP3. It affects men exclusively because of its recessive pattern 
of heredity linked to the X chromosome and is often fatal in the first year of life unless it is 
rescued with bone marrow transplantation. Clinically, IPEX presents a triad of autoimmune 
enteropathy, autoimmune endocrinopathy, and eczematous dermatitis. The most common 
manifestation is enteropathy followed by endocrinopathy, especially type 1 insulin- dependent 
diabetes mellitus. Additional manifestations described include immune- mediated cytopenia, 
which may present as neutropenia, anemia and/or thrombocytopenia, and  autoimmune 
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 nephropathy, hepatitis, and pulmonary disease. Food allergy with high serum IgE and eosin-
ophilia. Patients with IPEX generally have a wide range of autoantibodies due to adaptive 
immune dysregulation. The only curative treatment available for this disease is the alloge-
neic hematopoietic stem cell transplantation with chemotherapy of reduced intensity. Prior to 
transplantation, patients require nutritional support and immunosuppressive therapy, which 
may include glucocorticoids and/or steroid-sparing agents, such as calcineurin inhibitors, 
rapamycin inhibitor (mTOR) [11].
Single nucleotide polymorphism (SNP) 7340C>T is related to the development of autoim-
mune diseases and allergies in children. This polymorphism alters the stability of FOXP3 
mRNA by preventing translation. In addition to SNPs in FOXP3 itself, SNPs in three other 
loci indirectly affect FOXP3 expression and are associated with autoimmunity: CD25, PTPN2, 
and PTPN22. All three genes are involved in the response to IL-2. Tregs do not produce IL-2, 
but this interleukin is essential for its survival and function. The low expression of CD25 is 
associated as STAT5 after exposure to IL-2, with decreased Tregs throughout life in patients 
with type 1 diabetes and multiple sclerosis. The polymorphism rs3761549 G/A is related to 
the development of Graves' disease in children. These changes related to FoxP3 protein are 
commonly known as IPEX-type changes [40–43].
3. Treg-cell therapy
The use of Treg cells in clinical practice was made possible after isolation and enhancement 
of GMP (good manuring practice) CD4+CD25+ Treg cells with a yield of approximately 90% 
Treg, allowing the cryopreservation and expansion of these cells. Cell therapy with Treg has 
a purpose in the treatment of diseases, which result in a decompensated or undesired sup-
pressed Treg activity in cancer, immunoglobulin deficiency, autoimmune or inflammatory 
diseases, and deleterious consequences of immunosuppression after organ transplantation. 
Therefore, the manipulation of Treg cells can control the progression of cancer through cell 
configurations, solid organ transplantation and hematopoietic cells, transplant rejection, and 
autoimmune diseases. The concept of cellular immunotherapy with Treg is to give the patient 
Treg cells to decrease the exaggerated immune response to autoimmune diseases, organ 
transplants and bone marrow [44–47]. The nTreg cells, in vitro, can be expanded by antigenic 
stimulation in the presence of a high concentration of IL-2. In vivo, low-dose IL-2 treatment 
increases Treg expansion and is used in the treatment of graft versus host disease (GVHD) 
and hepatitis C virus-induced cryoglobulinemic vasculitis and, together with rapamycin. Low 
dose IL-2 was chosen to preferentially expand Treg cells without also expanding activated 
effector T cells. Modulation of IL-2 homeostasis is an important mechanism by which Treg 
modulates effector differentiation of CD8+ under strongly immunogenic conditions [48, 49]. 
Some authors suggest the use of rapamycin for Treg expansion in vivo with an approximately 
75–80% yield of pure cells and total depletion of CD8 and CD19 [50–52].
Three categories of GMP-grade clinical Treg can define: first generation (CD4+CD25+); sec-
ond generation, bone fide Treg (CD4+CD25+CD127low/−) and third generation naive Treg 
(CD4+CD25+CD127low/−CD45Ra+). These three types of Treg can be isolated and expanded 
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by Il-2 [46]. The main obstacle to Tregs expansion in the laboratory is iTregs instability. The 
use of the Nrp1 protein reduces the phosphorylation of the Akt protein, promoting cell sta-
bility. Demethylation of the CpG islands in the CNS2 region at the FOXP3 locus recruits 
transcription factors, including STAT5, NFAT, Runx1/Cbfb, CREB and FOXP3 itself, making 
the tTregs stable. However, demethylation in the CNS2 region of FOXP3 is known to render 
iTregs unstable. The control of the methylation/demethylation processes of the CNS1 and 
CNS2 regions of the FOXP3 gene of the iTregs is still not possible with 100% efficacy in the 
laboratory. In this way, it compromises clonal expansion in vitro, and several transcription 
factors are involved [47, 53].
3.1. Graft-versus-host disease (GVHD)
Allogeneic stem cell transplantation presents a series of problems, among which we can 
highlight GVHD, with high mortality rates of 15–30% in transplanted patients and 50% of 
morbidity. Treg cells are a novel approach based on cellular immunotherapy to reduce the 
risk of severe acute lesions of graft versus host disease (aGVHD). These lesions may occur 
within 100 days after transplantation. Chronic GVHD takes about 2–5 years for the signs and 
symptoms of the diseases to appear in the transplanted patient due to the presence of effector 
T cells in the marrow receptor tissue. To combat this reaction, aggressive immunosuppressive 
therapies are started, often unsuccessful. Despite the advances in GVHD treatment, the high 
rates of death are still high [54–56]. The development of acute and chronic forms of GVHD 
is different with signs and symptoms because it involves cells cytotoxic TCD8+ and helper 
TCD4+, and these cells activate different pathways in the autoimmune response. The pathway 
involving donor TCD8+ cells is activated when binding of TCR to major class I histocompat-
ibility complex (MHC-I) peptides occurs, and interaction the patient antigen-presenting cells 
(APCs), with the release of granzins, perforins, and production of inflammatory cytokines. 
Although activation of donor TCD4+ cells results in the activation of a Th1 inflammatory 
response with high production of INF-Y, IL-12, and IL-2, or a Th2-mediated inflammatory 
response with extensive production of IL-4, IL-5, IL-6 and IL-10 [54, 57].
After the haematopoietic stem cell transplantation (HSCT), reconstituted Treg cells express 
markers of recent thymic emigrants. These markers increase the number of native Treg cells in 
the population of graft-derived Treg cells after HSCT. Second, Treg Helios+ cells from patients 
receiving HSCT express higher levels of naive markers (such as CD45RA and CD31) than 
those from patients with active systemic lupus erythromatosus. This increase in Treg controls 
the immune responses of Th1 and Th2. Infusion of Treg cells into HSCT has been explored in 
murine and human models. Infusion of Treg cells during allogenic HSCT reduces acute and 
chronic graft-versus-host disease [58]. Patients with HSCT demonstrated that the use of IL-2 
at the dose of 1 × 106 IU per square meter decreases the chances of developing GVHD, in which 
the number of Treg increased due to activation of the FOXP3+ gene by IL-2, and the amount 
of Tcon decreased [51]. The immunological reaction of cGVHD exhibits phosphorylation of 
the transcription factor STAT5, increase of IL-17, IL-15 and deficiency or decrease of IL-2, The 
IL-2 therapy increased cell proliferation in the thymic and decrease apoptosis by activates 
phosphorylation of STAT5 [59]. Another alternative for Treg  expansion is CD28 stimulation 
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of pTregs, which results in a polyclonal expansion and preservation of a Treg phenotype 
and function as indicated by the high level FOXP3/Helios expression, reduced prokaryotic 
cytokine expression, inflammatory and powerful suppressive function [60]. Tr1 cells express 
CD49b and Lag3, producing IL-10. Tr1 cells play a role in tolerance but are distinct from 
FOXP3+ Tregs. Studies to examine these cells in organ transplantation are being initiated. The 
association between immunosuppressive drugs that increase the serum concentration of IL-2 
to induce Treg has also been gaining strength in the treatment of GVHD [61–65].
3.2. Type 1 diabetes
Type 1 diabetes mellitus (T1DM) is a chronic disease that results from the autoimmune 
destruction of insulin-producing pancreatic beta cells. May be associated with the develop-
ment of IPEX [66]. The death of β cells occurs due to exposure of their antigens to MHC 
class II complex APC cells and presentation to TCD4+ lymphocytes in the lymphatic mod-
ules of the pancreas. After presentation, TCD4+ cells differentiate into self-reactive effector 
TCD4+ (Teffs). The fractions of the complement system C3a and C5a facilitate the expansion 
and the function of Teff. In pancreatic islets, activated Teffs release cytokines including IFN-γ 
and IL-2, resulting in the recruitment of cytotoxic T lymphocytes and TCD8+ lymphocytes. 
Cytotoxic inflammatory cells eventually infiltrate and destroy the islet cells in a process called 
“insulite”, with the release of perforins and granzins AND release of IFN-γ, TNF α, IL-1β by 
macrophages. Chemokines released by the injured β-cells promote recruitment of additional 
mononuclear cells and the release of additional autoantigens allows the expansion and propa-
gation of the self-reactive Teff response [67–71]. In the pathogenesis of T1DM, the immune 
response is exaggerated against its own antigens. There is an imbalance between Tregs and 
effector T cells. Isolation and expansion ex vivo of Tregs CD25+CD127low/−CD25+ showed 
improved function and retained their diversity of T cell receptors, then these cells were used 
in T1DM patients. The infusions were well tolerated and with good safety. The use of pharma-
cotherapy including anti-CD3 therapy, glutamic acid decarboxylase (GAD) injection, hema-
topoietic stem cell transplantation (HSCT), autologous umbilical cord blood transfusion and 
stem cell educator therapy has demonstrated efficacy with increased levels of C-peptides and 
decrease in the daily dose of insulin [72, 73].
The subpopulations of Tregs in T1DM are different when compared to healthy individu-
als. The proportion of cells CD25low/− between cells Treg CD4+FOXP3+In T1DM patients was 
higher than in healthy patients. Low or no CD25 expression implies a decrease in Treg cell 
differentiation with decreased peripheral suppressor activity and increased Teff cell growth 
[74, 75]. The difficulty in using expanded Tregs ex vivo in patients with T1DM is found in 
the cells themselves since these cells express CD45RO+ memory phenotype. Another issue 
is the expression of Helios by lymphocytes in peripheral blood. Expanded lymphocytes in 
vitro have a lower expression of the molecule on their surface when compared to their own 
lymphocytes. However, the activity of suppressing autologous or allogeneic TCD8+ effector 
cells is maintained. Thus, it becomes a good alternative in the treatment of T1DM in the long 
term. Some studies have conflicting results on the use of Treg cells in the treatment of T1DM 
since several mechanisms are involved in the T1DM pathology; however, they are in line with 
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lack, dysregulation or deficiency of local and peripheral Treg [76]. Studies with the use of IL-2 
in the treatment of T1DM have demonstrated effective results in the expansion of Treg [77].
3.3. Autoimmune hepatitis and systemic lupus erythematosus
The inflammatory response of autoimmune hepatitis (AIH) involves the B-lymphocytes, 
T cells, Th1, Th17 and cytotoxic T cells. Studies have shown that the function of the mature 
FOXP3 protein shows inactivity in T CD4+ cells. Cell therapy, such as the infusion of 
autologous, antigen-specific and hepatic regulatory T cells to restore hepatic immune tol-
erance, may soon be a potential future treatment for patients with AIH [78, 79]. Hepatic 
tolerance is involved in the pathogenesis of autoimmune hepatitis, with an imbalance of 
immune responses. There are controversies in scientific research regarding the number 
of Treg present in AHI. Though the modulating function of the cell appears to be com-
promised [80, 81]. However, in treated patients with IL-2, the Treg number is higher than 
untreated patients. This fact supports the hypothesis of treating patients with autologous 
Tregs expanded ex vivo and may lead to tolerance to hepatic antigens during the develop-
ment of chronic disease, with remission of the clinical signs and symptoms of AIH. The 
use of IL-2 for Treg expansion in vivo is an option for treatment in patients with reduced 
Treg numbers [82–84].
SLE is a chronic autoimmune disease characterized by the production of antinuclear auto-
antibodies of the IgG type. Symptoms of the disease include light hypersensitivity, impaired 
joints, thyroid dysfunction, changes in the central nervous system and renal filtration [85]. 
There is growing evidence that Th1, Th2, Th9, and Th17 cells are associated with the patho-
genesis of SLE. Disorders related to the amount, function of Treg show a worse evolution 
in the disease and decrease the production of IL-2. But studies that demonstrate this com-
mitment are not homogeneous [86]. The use of IL-2 in the treatment of SLE demonstrated 
decreased exaggerated inflammatory response and increased proliferation of Tregs in vivo 
[87–90]. Treg cells expressing Helios are used with functional suppressive capacity and 
migratory potential in inflamed tissues is expanded in active SLE, presumably by γ-chain 
signaling cytokines and TCR stimulation, to compensate for autoreactive effector responses 
[91]. Treatment with melatonin increases the frequency of CD3+CD4+FOXP3+ cells and the 
mean fluorescence intensity of FOXP3 in patients with SLE [92].
3.4. Rheumatoid arthritis and multiple sclerosis
Rheumatoid arthritis is characterized by chronic inflammation of the joints, with severe 
pain and in the long term, loss of movement of the affected joint. In the development of 
rheumatoid arthritis, Treg cells are unable to suppress inflammatory responses, with an 
imbalance between Treg effector cells and TCD4+ cells. Low doses of IL-2 increase Treg 
stimulation in rheumatoid arthritis [93, 94]. In rats, depletion of Treg cells results in the 
onset of a variety of autoimmune diseases, including arthritis. Treg's cellular replacement 
relieves the symptoms of the disease. The importance of Treg cells in rheumatoid arthritis 
is supported by the efficacy of CTLA4-Ig therapy, an increased ratio of Treg cells/effector 
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T cells after treatment with  anti-IL-6R or anti-TNF-α and the identification of CTLA-4 asso-
ciated with rheumatoid  arthritis. FOXP3+ T cells are able to convert into pathogenic Th17 
cells. Th17 cells are increased in rheumatoid arthritis, being responsive for the production of 
inflammatory cytokines and the activation of inflammation in severe cases. The modulation 
between Treg/Th17 is an alternative for the immunocellular treatment of rheumatoid arthri-
tis [95–97]. Tregs play a key role in protecting individuals against autoimmunity. Many 
studies suggest that the amount of Treg may be a protective factor against the development 
of multiple sclerosis. The use of TGF-β may be an alternative aid in the treatment of multiple 
sclerosis, since Treg and effector T cells are defective. The causes of multiple sclerosis are 
still unknown, but the immune system plays a central role in the development of the disease 
[98, 99].
4. Conclusion
The success of Treg cell therapy depends initially on the isolation and characterization of 
cells. New studies are emerging, with the discovery of new cell markers for the identification 
of Treg. However, current research does not use a universally applicable standard for Treg 
identification. This gap in identification leads to conflicting and doubtful research results. The 
cellular variability of Treg is wide. It is important to characterize the phenotype and suppres-
sor function of each subtype of Treg present in the periphery or in the thymus. The deregula-
tion of these cells leads to the development of autoimmune diseases or the worsening of the 
clinical picture of these diseases. The FOXP3 protein is responsive to Treg cell suppressor 
activity, together with other molecules. Understanding the modulation pathway to activate 
the FOXP3 gene is important for the expansion of stable Tregs in vitro and that in the future 
we will have effective cellular therapy without damage to the organism.
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